Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis to acquire Medley

Sanofi-aventis has signed an agreement to acquire Brazilian generics drug manufacturer Medley in a deal that values the company at €500m

Sanofi-aventis has signed an agreement to acquire Brazilian generics drug manufacturer Medley in a deal that values the company at €500m.

The transaction comes on the heels of the French company's purchase of Mexican generics drug maker Laboratorios Kendrick for an undisclosed amount earlier this year and its purchase of Czech generics maker Zentiva.

It will allow sanofi-aventis to "build-up on growth platforms, accelerate sales and further extend its pharmaceutical portfolio in emerging markets," a spokesperson said. And "reinforce [sanofi-aventis'] number one ranking among pharmaceutical companies in Brazil, with a total 12 per cent market share."

Sanofi-aventis is a market leader in the antithrombic area and its anticlotting drugs Lovenox and Plavix are predicted to be major growth drivers to 2012, when the group's maturing product portfolio will face generic competition.

Medley is the third largest pharmaceutical company and the number one generic company in Brazil. In 2008, its sales amounted to 458 million Brazilian reais, around €153m, with generics counting for two thirds of that.

With a generics portfolio of 127 products, Medley is very well positioned to benefit from the growth of the Brazilian generics market, which is expected to remain over 20 per cent per year in coming years.

14th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics